AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug
29-08-2017
Takeda enters $100m licensing agreement with Tesaro
01-08-2017
Jonathan Weiss / Shutterstock.com
Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Takeda, Par Pharmaceuticals, US District Court for the District of Massachusetts, KPH Healthcare Services, Kinney Drugs
